CLDN18 and neoplasm: Xu et al. published the results of the application of a novel anti-CLDN18.2/anti-CD3 bispecific antibody, which exhibited low affinity for anti-CD3, highly specific binding, potent cytotoxicity, and anti-tumor activity [30].